<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744288</url>
  </required_header>
  <id_info>
    <org_study_id>D5130C00079</org_study_id>
    <nct_id>NCT01744288</nct_id>
  </id_info>
  <brief_title>Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets</brief_title>
  <official_title>A Open Label, Randomized, Crossover and Potential Parallel, Single Dose Study of Ticagrelor 180 mg and Acetylsalicylic Acid (ASA) in Healthy Volunteers Followed by Autologous in Vivo Platelet Transfusion to Determine the Effects of Platelet Supplementation on the Reversibility of Platelet Inhibition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Study to see if platelet transfusion stop or lessen the effect of the drug on platelets
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A open label, randomized, crossover and potential parallel, single dose study of ticagrelor
      180 mg and acetylsalicylic acid (ASA) in healthy volunteers followed by autologous in vivo
      platelet transfusion to determine the effects of platelet supplementation on the
      reversibility of platelet inhibition
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics in terms of percent of inhibition of adenosine phosphatase (ADP)-induced platelet aggregation assessed by light transmission aggregometry (LTA) after loading dose of Ticagrelor</measure>
    <time_frame>Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics in terms of platelet reactivity as measured by P2Y12 Reaction Units (PRU) using VerifyNow™ after loading dose of Ticagrelor</measure>
    <time_frame>Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics in terms of platelet reactivity as measured by P2Y12 Reaction Units (PRU) using VerifyNow™ after loading dose of Clopidogrel</measure>
    <time_frame>Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics in terms of percent of inhibition of adenosine phosphatase (ADP)-induced platelet aggregation assessed by light transmission aggregometry (LTA) after loading dose of Clopidogrel</measure>
    <time_frame>Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile in terms of adverse events, blood pressure, pulse, temperature, ECG (Electrocardiogram), physical examination, and safety laboratory variables</measure>
    <time_frame>up to 9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Inhibition on Platelet Aggregation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor with Platelet transfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor without Platelet transfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel with Platelet transfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel without Platelet transfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Oral single loading dose 180ng</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Oral single loading dose 600mg</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA</intervention_name>
    <description>81mg once daily from day -2 up to platelet transfusion</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

          -  Healthy male and/or female volunteers aged 18 to 50 years, inclusive, with suitable
             veins for cannulation or repeated venipuncture. (Healthy as determined by medical
             history and physical examination, laboratory parameters, electrocardiogram (ECG)
             perform

          -  Have a body mass index (BMI) between 18 and 35 kg/m2 (inclusive) and weigh at least 50
             kg and no more than 120 kg

        Exclusion Criteria:

          -  ADP induced platelet aggregation &lt;60% prior to platelet apheresis

          -  History of peptic ulcer disease Healthy volunteers with a propensity to bleed (eg, due
             to recent trauma, recent surgery, active or recent gastrointestinal bleeding or
             moderate hepatic impairment)

          -  Any clinically significant illness, medical/surgical procedure or trauma within 4
             weeks of the first administration of the investigational product

          -  Current smokers, those who have smoked or used nicotine products within the previous 3
             months and those who tested positive for cotinine at screening or at admission to the
             study center
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Carlson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Wilmington US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phil Leese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Overland Park US, Quintiles, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judi Hsia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wilmington, US AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2012</study_first_submitted>
  <study_first_submitted_qc>December 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>April 23, 2014</last_update_submitted>
  <last_update_submitted_qc>April 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1 Safety ,</keyword>
  <keyword>pharmacodynamic,</keyword>
  <keyword>Ticagrelor,</keyword>
  <keyword>Clopidogrel,</keyword>
  <keyword>Platelets</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

